**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 54699

**Manuscript type:** CASE REPORT

**Demyelinating polyneuropathy and lymphoplasmacytic lymphoma coexisting in 36-year-old man: A case report**

Rozlucka L *et al.* Coexistence of polyneuropathy and lymphoplasmacytic lymphoma

Lesia Rozłucka, Elżbieta Semik-Grabarczyk, Marta Pietrukaniec, Agnieszka Żak-Gołąb, Małgorzata Grabarczyk, Sebastian Grosicki, Michał Holecki

**Lesia Rozłucka,** Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice 40-752, Poland

**Elżbieta Semik-Grabarczyk, Marta Pietrukaniec, Agnieszka Żak-Gołąb, Michał Holecki,** Department of Internal Medicine, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice 40-752, Poland

**Małgorzata Grabarczyk**, Student Scientific Society at the Department of Internal Medicine, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice 40-752, Poland

**Sebastian Grosicki**, Department of Hematology and Cancer Prevention, Faculty of Health Sciences in Bytom, Medical University of Silesia, Bytom, 41-902, Poland

**Author contributions:** Rozlucka Lwas patients’ doctor, drafted and prepared manuscript for final publication; Semik-Grabarczyk E and Grabarczyk M reviewed the literature and drafted the manuscript; Pietrukaniec M and Żak-Gołąb A contributed to manuscript drafting and translated the manuscript; Grosicki S performed hematology consultation and revised the manuscript; Holecki M was responsible for the revision of the manuscript for important intellectual content. All authors issued final approval for the version to be submitted.

**Corresponding author: Lesia Rozłucka, MD, Doctor,** Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medykow 14, Katowice 40-752, Poland. lesia.rozlucka@gmail.com

**Received:** February 24, 2020

**Revised:** May 20, 2020

**Accepted:** May 23, 2020

**Published online:**

**Abstract**

BACKGROUND

Lymphoplasmacytic lymphoma is a rare non-Hodgkin’s lymphoma, occurring mostly in the elderly. It develops slowly and leads to malignant proliferation of lymphoid line cells in the bone marrow, lymph nodes and spleen. It may also affect nerve roots and meninges; some patients develop sensorimotor polyneuropathy which may precede general symptoms of lymphoma.

CASE SUMMARY

We present a case of a 36-year-old man diagnosed in 2012 with chronic inflammatory demyelinating polyneuropathy (CIDP), then he was hospitalized in 2019 due to progressive symptoms of heart failure and significant weight loss over the previous four months. Based on clinical and laboratory findings a diagnosis of lymphoplasmacytic lymphoma was suspected and confirmed by bone marrow flow cytometry. There was no improvement in the results of laboratory tests and the patient's condition after immediate implementation of chemotherapy. Patient died on the fifth day of treatment.

CONCLUSION

While CIDP and malignant disease co-occurrence is rare, it should be suspected and investigated in patients with atypical neuropathy symptoms.

**Key words:** Lymphoplasmacytic lymphoma; Chronic inflammatory demyelinating polyneuropathy; Polyneuropathy; Paraneoplastic neuropathy; Autoimmunity; Case report

Rozłucka L, Semik-Grabarczyk E, Pietrukaniec M, Żak-Gołąb A, Grabarczyk M, Grosicki S, Holecki M. Demyelinating polyneuropathy and lymphoplasmacytic lymphoma coexisting in 36-year-old man: A case report. *World J Clin Cases* 2020; In press

**Core tip:** Lymphoplasmacytic lymphoma is a low-grade B cell type of non-Hodgkin's lymphoma. It occurs mainly in elderly, develops slowly and leads to malignant proliferation of lymphoid line cells in the bone marrow. In some cases, patients develop polyneuropathy, which may precede the general symptoms of lymphoma. We present a case of a young man with chronic inflammatory demyelinating polyneuropathy since 2012. His neurological condition worsened rapidly seven years later, which turned out to be paraneoplastic symptom of aggressive lymphoplasmacytic lymphoma. The lack of typical hematological symptoms resulted in delaying the diagnosis and fatal outcome.

**INTRODUCTION**

Chronic inflammatory demyelinating polyneuropathy (CIDP), the most common chronic autoimmune polyneuropathy, is a rare neuromuscular disorder of spinal nerve roots, major plexuses, and the proximal nerve trunks. Its incidence is estimated to be 1.6/100000 per year with a prevalence of 8.9/100000[1]. CIDP mainly occurs between the 3th and 6th decade, slightly more often in men[2,3]. It may be associated with viral infections (*e.g.*, hepatitis C, human immune deficiency virus), connective tissue disease, hyperthyroidism, diabetes mellitus, but also with hematological diseases, the diagnosis of which may often be preceded by CIDP[4]. The clinical manifestations of CIDP include progressive, symmetric paresis and weakness of the proximal and distal parts of upper and lower limbs. Paresis effects roots, plexuses or nerve trunks, which results in general paresthesia, sensation (touch, pain, temperature) loss and balance problems. Cranial nerves are occasionally affected. The complete clinical symptoms develop gradually within two months[5]. The course of the disease can be: (1) Monophasic; (2) Chronic and progressive; and (3) Variant with periods of remission and relapses. Due to the similar clinical and pathological course, the differential diagnosis of CIDP should include Guillaine-Barré (GB) syndrome[2,6]. Lymphoplasmacytic lymphoma (LPL) is a rare B-cell type of non-Hodgkin’s lymphoma. It originates from small mature B cells, that can differentiate into plasma cells[7,8]. The prevalence is about 2% of blood cancers, and the annual incidence is six per million people. The disease usually affects older adults (the average age at the moment of diagnosis is 63-68), it develops slowly and leads to malignant proliferation of lymphoid line cells in the bone marrow[9,10]. Approximately 30% of patients develop symmetrical sensorimotor polyneuropathy (multifocal or mononeuropathy), which may precede general symptoms of lymphoma[11].

CIDP has been described in association with different malignancies. The most common are lymphomas. Thirteen patients with lymphoma described by Viala *et al*12] suffered from CIDP. Seven of them had non-Hodgkin B-cell lymphoma, two non-Hodgkin T-cell lymphoma and remaining four Hodgkin Lymphoma[12]. Another study analyzed fifty-three patients with lymphoma and various paraneoplastic neurologic symptoms. While cerebral degeneration was mainly associated with Hodgkin lymphomas, in patients with non-Hodgkin lymphomas (all B-cell) the most common manifestation of neurologic symptoms was acute or chronic demyelinating polyradiculoneuropathy[13].

**CASE PRESENTATION**

***Chief complaints***

A 36-year-old man diagnosed with CIDP and hypothyroidism seven years ago, was admitted in April 2019 to the Department of Internal Medicine, Autoimmune and Metabolic Diseases due to progressive weakness, peripheral edema, weight loss (approximately 10 kg within the previous four months, 31 kg in total since CIDP diagnosis), deterioration of appetite and impairment of the muscular system (the patient moved around the house with the help of others). On admission, the patient complained of "stiffness of the torso", sensory disturbances affecting hands and feet in a glove and stocking distribution.

***History of present illness***

The patient's condition deteriorated significantly about five months before admittance, with particular aggravation of symptoms during the last month. In December 2018 patient was hospitalized due to concomitant edema, protein deficiency and heart failure. Despite intensive diuretic treatment, the improvement was temporary. In the meantime, due to increasing abdominal pain, patient underwent gastroscopy and was diagnosed with gastritis. Proton pomp inhibitors treatment resulted in only partial improvement. The patient's neurological condition continued to deteriorate despite intravenous immunoglobulin and glucocorticosteroid treatment leading to his necessity of hospitalization.

***History of past illness***

Patient wasdiagnosed with CIDP and hypothyroidism in 2012. Since then he was treated using INN–human normal immunoglobulin (Kiovig 60 mg), with the last administration one month before current hospitalization and methylprednisolone (in intravenous pulses followed by an oral therapy). Hypothyroidism was treated with Levothyroxine (50 μg/d).

***Personal and family history***

Patients’ grandfather died of cancer of unknown localization and mother was treated in the past due to thyroid cancer.

***Physical examination upon admission***

Physical examination revealed dry, thickened, slightly flaky skin of the whole body and swelling of the lower limbs was also noticeable. Peripheral lymph nodes were not palpable. His body weight was 55 kg, height 178 cm (BMI 17.3 kg/m2). Neurological examination revealed disturbances of deep sensation and vibration sense in the lower limbs, reduction of muscle tone in the limbs except for the hands, symmetrical muscle wasting in the face, upper and lower limbs.

***Laboratory examinations***

The results of laboratory tests are presented in Table 1. The overall clinical picture, as well as the results of laboratory and imaging studies suggested a secondary nature of polyradiculoneuropathy. Despite the negative opinion of a neurologist, the patient underwent a bone marrow aspiration. Bone marrow cytology showed an increased percentage of plasmocytes, which strongly suggested a hematological background.

***Imaging examinations***

The abdomen ultrasonography revealed abdominal lymphadenopathy and accumulated pericardial and peritoneal fluid. Computed tomography (CT) scan of the chest, abdomen and pelvis revealed streaky fibrous changes at the base of the left lung, and numerous enlarged mesenteric lymph nodes (up to 14 mm × 29 mm, Figure 1).

**MULTIDISCIPLINARY EXPERT CONSULTATION**

***Sebastian Grosicki, MD, PhD, Professor and Chief of Hematology Department, Medical University of Silesia, Poland***

In the course of diagnostics, an increased pool of lymphoid cells in the myelogram was found and the patient was referred for further diagnosis in the Hematology Department. Fifty-five percent infiltration with clonal plasma, lymphoplasmic and B cells was confirmed in immunophenotype and bone marrow morphology (Figure 2). Increased concentration of free kappa light chains in peripheral blood serum and urine, and the presence of M protein in the IgM kappa class in serum was confirmed. In peripheral blood counts, leukocytosis 21.9 × 103/μL (normal range 4.0 × 103/μL-10.0 × 103/μL) with granulocytosis, microcytic, sideropenic anemia and reactive thrombocytosis have been noted.

**FINAL DIAGNOSIS**

Taking into account all the symptoms, a diagnosis of LPL was stated.

**TREATMENT**

Given the rapidly worsening clinical condition of the patient, R-COP (rituximab 600 mg iv 1 d, vincristin 2 mg iv 1 d, cyclophosphamide 1200 mg iv 1-5 d, methylprednisolone 125 mg iv 1-5 d,) immunochemotherapy as an emergency treatment was started. Unfortunately, despite intensive supportive treatment the general clinical and neurological condition of the patient deteriorated.

**OUTCOME AND FOLLOW-UP**

The patient died on the fifth day of treatment in the Hematology Department.

**DISCUSSION**

Lymphomas, more commonly B-cell lymphomas including LPL may cause axonal damage or infiltrate peripheral nerves and cause asymmetric mononeuropathy or CIDP[14]. Therefore, there are a number of reports regarding occurrence of CIDP in the course of lymphoma, but only a few describing paraneoplastic CIDP, which precede the lymphoma diagnosis[15-17]. Vial *et al*12] presented nine cases in which CIDP symptoms preceded lymphomas, but none of them where LPL. However, they described a case of 39-year-old man with axonal multiple mononeuropathy which occurs six months before LPL diagnosis and 79-year-old woman with radiculopathy, in whom LPL was diagnosed five months after the first symptoms of radiculopathy. In the first case treatment included doxorubicin-based therapy, intrathecal methotrexate/cyclophosphamide and fludarabine. The second patient was treated with doxorubicin, intrathecal methotrexate and prednisone. In both cases hematological remission and neurological improvement were observed[12].

The patient described by us is an example of paraneoplastic polyradiculoneuropathy and lymphoplasmacytic lymphoma. CIDP was initially diagnosed in 2012, since when remissions and relapses were observed alternately. The patient was treated monthly with intravenous immunoglobulins (Kiovig), and with intermittent intravenous pulses of methylprednisolone sodium succinate (Solu-Medrol). This treatment was initially effective – the patient was able to function normally in everyday life (he worked as a mechanic in the workshop, often travelled abroad, actively spending his spare-time). However, in December 2018 his general health condition (especially neurological) deteriorated. The rapid weight loss was attributed to the intensive diuretic treatment due to concomitant edema, which in turn were caused by protein deficiency and heart failure (not typical for such a young man). Due to increasing abdominal pain, patient underwent gastroscopy and was diagnosed with gastritis. Proton pomp inhibitors treatment resulted in only partial improvement. The patient's neurological condition continued to deteriorate despite intravenous immunoglobulin and glucocorticosteroid treatment leading to his necessity of hospitalization.

The overall clinical symptoms, the results of laboratory tests and CT scan suggested the secondary background of polyradiculoneuropathy. Despite the different opinion of the neurologists, we stayed with our suspicion of a diagnosis of lymphoma, which was finally confirmed. It seems that the lack of typical symptoms, such as peripheral lymphadenopathy, splenomegaly or low-grade fever, resulted in delaying the diagnosis of lymphoma and worsening its’ prognosis. Disturbing symptoms reported by the patient were not considered to have paraneoplastic origin. It seems reasonable, that such asymptomatic patients should have regular basic laboratory tests such as blood count, blood biochemistry and proteinogram, as well as chest X-ray and an abdominal ultrasound. In case of any abnormalities bone marrow biopsy and hematologist consultation should be done. Polyradiculoneuropathy, while mostly primary, may also by secondary to LPL. Such a situation, when symmetrical sensorimotor polyneuropathy (multifocal or mononeuropathy) precedes the diagnosis of lymphoma, is observed even in 30% of patients. This case should be a reminder to consider an oncological diagnosis in patients with CIDP, especially those with an atypical or rapidly progressive course of the disease.

**CONCLUSION**

CIDP and malignant diseases co-occurrence is rare, nevertheless patients with atypical symptoms of neuropathy should have extended diagnostics and remain under constant supervision of specialists.

**REFERENCES**

1 **Laughlin RS**, Dyck PJ, Melton LJ 3rd, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. *Neurology* 2009; **73**: 39-45 [PMID: 19564582 DOI: 10.1212/WNL.0b013e3181aaea47]

2 **Dalakas MC**; Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. *Nat Rev Neurol* 2011; **7**: 507-517 [PMID: 21844897 DOI: 10.1038/nrneurol.2011.121]

3 **Peltier AC**, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. *Semin Neurol* 2012; **32**: 187-195 [PMID: 23117943 DOI: 10.1055/s-0032-1329194]

4 **Vallat JM**, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. *Lancet Neurol* 2010; **9**: 402-412 [PMID: 20298964 DOI: 10.1016/S1474-4422(10)70041-7]

5 **Dimachkie MM**, Barohn RJ. Chronic inflammatory demyelinating polyneuropathy. *Curr Treat Options Neurol* 2013; **15**: 350-366 [PMID: 23564314 DOI: 10.1007/s11940-013-0229-6]

6 **Ruts L**, Drenthen J, Jacobs BC, van Doorn PA; Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. *Neurology* 2010; **74**: 1680-1686 [PMID: 20427754 DOI: 10.1212/WNL.0b013e3181e07d14]

7 **Campo E**, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. *Blood* 2011; **117**: 5019-5032 [PMID: 21300984 DOI: 10.1182/blood-2011-01-293050]

8 **NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).** Waldenstrom’s Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 2.2011. National Comprehensive Cancer Network. Available from: http://williams.medicine.wisc.edu/waldenstroms.pdf

9 **Anagnostopoulos A**, Hari PN, Pérez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. *Biol Blood Marrow Transplant* 2006; **12**: 845-854 [PMID: 16864055 DOI: 10.1016/j.bbmt.2006.04.010]

10 **Ansell SM**, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. *Mayo Clin Proc* 2010; **85**: 824-833 [PMID: 20702770 DOI: 10.4065/mcp.2010.0304]

11 **Baldini L**, Nobile-Orazio E, Guffanti A, Barbieri S, Carpo M, Cro L, Cesana B, Damilano I, Maiolo AT. Peripheral neuropathy in IgM monoclonal gammopathy and Wäldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. *Am J Hematol* 1994; **45**: 25-31 [PMID: 7504399 DOI: 10.1002/ajh.2830450105]

12 **Viala K**, Béhin A, Maisonobe T, Léger JM, Stojkovic T, Davi F, Leblond V, Bouche P. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? *J Neurol Neurosurg Psychiatry* 2008; **79**: 778-782 [PMID: 17971432 DOI: 10.1136/jnnp.2007.125930]

13 **Briani C**, Vitaliani R, Grisold W, Honnorat J, Graus F, Antoine JC, Bertolini G, Giometto B; PNS Euronetwork. Spectrum of paraneoplastic disease associated with lymphoma. *Neurology* 2011; **76**: 705-710 [PMID: 21339498 DOI: 10.1212/WNL.0b013e31820d62eb]

14 **Kelly JJ**, Karcher DS. Lymphoma and peripheral neuropathy: a clinical review. *Muscle Nerve* 2005; **31**: 301-313 [PMID: 15543550 DOI: 10.1002/mus.20163]

15 **Viala K**, Stojkovic T, Doncker AV, Maisonobe T, Lenglet T, Bruneteau G, Musset L, Neil J, Léger JM, Leblond V. Heterogeneous spectrum of neuropathies in Waldenström's macroglobulinemia: a diagnostic strategy to optimize their management. *J Peripher Nerv Syst* 2012; **17**: 90-101 [PMID: 22462670 DOI: 10.1111/j.1529-8027.2012.00376.x]

16 **Levine T**, Pestronk A, Florence J, Al-Lozi MT, Lopate G, Miller T, Ramneantu I, Waheed W, Stambuk M, Stone MJ, Choksi R. Peripheral neuropathies in Waldenström's macroglobulinaemia. *J Neurol Neurosurg Psychiatry* 2006; **77**: 224-228 [PMID: 16421127 DOI: 10.1136/jnnp.2005.071175]

17 **Vallat JM**, De Mascarel HA, Bordessoule D, Jauberteau MO, Tabaraud F, Gelot A, Vallat AV. Non-Hodgkin malignant lymphomas and peripheral neuropathies--13 cases. *Brain* 1995; **118**: 1233-1245 [PMID: 7496783 DOI: 10.1093/brain/118.5.1233]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for hospitalization and performing diagnostic procedures.

**Conflict-of-interest statement:** None of the authors have any potential conflicts of interest to declare regarding this case report.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** February 24, 2020

**First decision:** April 24, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Poland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Sridharan G **S-Editor:** Wang J **L-Editor:** **E-Editor:**

**Figure Legends**



**Figure 1 Computed tomography scan revealing enlarged lymph nodes (marked by arrows) in abdominal cavity.**

**Obraz zawierający wewnątrz, obiekt, zegar, tort

Opis wygenerowany automatycznie**

**Figure 2 Microscopic view of patients’ bone marrow-lymphoplasmatic lymphoma infiltration.** 1: Plasmatic cell; 2: B cell; 3: Lymphoplasmatic cell.

**Table 1 Laboratory blood test results at hospital admission**

|  |  |  |
| --- | --- | --- |
|  | **Result** | **Normal range** |
| Hematology |  |  |
| White blood cell count | 20.31 × 103/µL | (4.0-10.0) |
| Red blood cell count | 4.93 × 106/µL | (4.2-5.7) |
| Hemoglobin | 12.3 g/dL | (13.5-6.5) |
| Hematocrit | 38.7% | (40-53) |
| MCV | 78.5 fL | (84-98) |
| MCH | 24.9 pg | (27-31) |
| MCHC | 31.8 g/dL | (32-36) |
| Platelets | 704 × 103/µL | (130-400) |
| Lymphocytes | 47.6% | (20-45) |
| Monocytes | 7.1% | (3–9) |
| Neutrophils | 44.2% | (45-70) |
| Eosinophils | 0.20% | (1.00-5.00) |
| Basophils | 0.4% | (0-1) |
| ESR | 9 mm/h | (3-8) |
| Coagulation | | |
| aPTT | 29.0 s | (25.4-36.9) |
| Thrombin time | 16.6 s | (10.3-16.6) |
| Prothrombin time | 11.3 s | (9.4-12.5) |
| INR | 1.00 ng/mL | (0.80-1.20) |
| D-dimer | 1744.0 | (< 500.0) |
| Biochemistry | | |
| C-reactive protein | 7.3 mg/L | (< 5.0) |
| Glucose | 116.00 mg/dL | (74.00-106.00) |
| Creatinine | 1.10 mg/dL | (0.84-1.25) |
| MDRD GFR | > 60 mL/min | (> 60) |
| Uric acid | 6.37 mg/dL | (3.50-7.20) |
| Lactate dehydrogenase | 196 U/I | (< 248) |
| Lactate (Lac) | 2.10 mmol/L | (1.10-2.40) |
| Alkaline phosphatase | 95 U/L | (38-126) |
| Alpha amylase | 75.0 U/L | (< 90.0) |
| Lipase | 44.00 U/I | (21.00-67.00) |
| Serum iron | 26.00 µg/dL | (60.00-180.00) |
| UIBC | 150.00 µg/dL | (155.00-300.00) |
| TIBC | 176.0 µg/dL | (250.0-450.0) |
| Total cholesterol | 133.0 mg/dL | (< 200) |
| Triglycerides | 160.00 mg/dL | (0.00-150.00) |
| Hormones | | |
| Anti-TPO | < 5.00 IU/mL | (< 34.00) |
| TSH | 5.230 µIU/mL | (0.27-4.2) |
| Cortisol | 12.60 µg/dL | (4.82-19.50) |
| Electrolytes | | |
| Sodium | 134.2 mmol/L | (136.0-146.0) |
| Potassium | 4.95 mmol/L | (3.50-5.10) |
| Calcium-total | 7.70 mg/dL | (8.80-10.60) |
| Phosphates inorganic | 3.95 mg/dL | (2.50-4.50) |
| Liver enzymes | | |
| ALT | 17.0 U/L | (< 45.0) |
| AST | 20.0 U/L | (< 35.0) |
| GGT | 15.00 U/L | (< 55.00) |
| Total bilirubin | 0.19 mg/dL | (0.30-1.20) |
| Cardiac biomarkers | | |
| Troponin T high sensitivity | 47.74 ng/L | (0.00-14.00) |
| Creatine Kinase | 41 U/L | (< 170) |
| Creatine Kinase -MB | 18 U/L | (< 25) |
| CKMB | 43.9% | (< 6.0) |
| Pro-BNP | 288.30 pg/mL | (0-125) |
| Serum protein electrophoresis | | |
| Albumin | 49.2% | (53.8-65.2) |
| Alpha 1 | 7.2% | (1.1-3.7) |
| Alpha 2 | 21.1% | (8.5-14.5) |
| Beta | 17.1% | (8.6-14.8) |
| Gamma | 5.4% | (9.2-18.2) |
| A/G ratio | 0.97 | (1.27-1.96) |
| Total protein | 4.30 g/dL | (6.60-8.30) |
| Albumin | 2.30 g/dL | (3.5-5.2) |
| Virology tests | | |
| Anti-HCV | negative |  |
| HbsAg | negative |  |
| Anti-HIV | negative |  |
| Immunoglobulins | | |
| Immunoglobulin A | 25 mg/dL | (70-400) |
| Immunoglobulin G | 193 mg/dL | (700-1600) |
| Immunoglobulin M | 142 mg/dL | (40-230) |
| Rheumatology profile | | |
| ANA profile | negative |  |
| Anti- CCP | 0.47 RU/mL | (< 5.00) |
| Anti- dsDNA | 13.9 IU/mL | (< 100) |
| p-ANCA | negative |  |
| c-ANCA | negative |  |
| Complement C3 | 134 mg/dL | (90-180) |
| Complement C4 | 35 mg/dL | (10-40) |
| Onconeural antibodies |  |  |
| Chromogranin A | 363.250 µg/L | (< 100) |
| Anti-neuronal autoantibodies | | |
| (Hu. Yo. Ri. CV2. Ma2/Ta. amphiphysin. anti-GAD) | negative |  |

MCV: Mean corpuscular volume; MCH: Mean corpuscular hemoglobin; MCHC: Mean corpuscular hemoglobin concentration; ESR: Erythrocyte sedimentation rate; MDRD GFR: Modification of diet in renal disease glomerular filtration rate; UIBC: Unsaturated iron binding capacity; TIBC: Total iron binding capacity; anti-TPO: Anti thyroid peroxidase; TSH: Thyroid stimulating hormone; aPTT: Activated partial thromboplastin time; INR: International normalized ratio; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; pro-BNP: B type natriuretic peptide; A/G: Albumin/globulin; HbsAg: Surface antigen of hepatitis B virus; anti-CCP: Anti cyclic citrullinated peptide; anti-dsDNA: Anti double stranded DNA; p-ANCA: Perinuclear antineutrophil cytoplasmic antibody; c-ANCA: Cytoplasmic antineutrophil cytoplasmic antibody.